Nasdaq:URGN
UroGen Pharma Ltd.
Clinical-stage biopharma company advancing oncology and rare disease therapies with a strong cash runway and strategic partnership revenue.
Key Metrics
Investment Thesis
Bull Case
Investors may consider URGN for its growing revenue profile from strategic partnerships which validates the commercial potential of its pipeline without immediate sales pressure. The company maintains a robust liquidity position with $173.1M in cash against only $294.5M in total liabilities, providing ample runway to advance assets into clinical trials. Successful data readouts could trigger significant value appreciation and attract further partnership interest.
Bear Case
The stock faces substantial risk as the company has accumulated a retained earnings deficit of over $806M with no commercial product revenue to generate sustainable profits. Recent equity issuances totaling $151.2M indicate ongoing dilution, which may continue if the company cannot achieve profitability or secure larger partnerships. High operating expenses relative to revenues suggest the business model is currently cash-burning, making it vulnerable to market downturns or funding constraints.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for oncology and rare diseases, primarily serving the United States and international markets through strategic partnerships. The company generates revenue primarily from collaboration agreements and milestone payments while investing heavily in research and development to advance its pipeline. With total assets of $285.7M and a significant cash position, UroGen is leveraging its scientific platform to address unmet medical needs in high-value therapeutic areas.
Analysis
Management Discussion
While revenue grew 41% year-over-year to $90.4M driven by collaboration milestones, the company posted a net loss of $126.9M, widening from prior years due to elevated general and administrative expenses of $121.2M and R&D spending of $57.1M. Despite negative operating cash flow of $96.8M, management successfully increased total cash and equivalents to $173.1M through financing activities, including $151.2M in common share issuances and $24.5M in debt issuances.
Industry Overview
The biopharmaceutical industry is characterized by high capital intensity and long development cycles, where companies often operate at a loss until products reach late-stage clinical trials or commercialization. Success depends heavily on securing strategic partnerships to share financial risk and regulatory burden while navigating stringent FDA approval processes for oncology and rare disease indications. Market dynamics favor firms with differentiated scientific platforms that can reduce attrition rates in competitive therapeutic spaces.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $64.4M | $82.7M | $90.4M |
| Cost of Revenue | $7.7M | $9.4M | $8.9M |
| Gross Profit | $56.7M | $73.4M | $81.5M |
| Operating Expenses | $135.7M | $138.9M | $178.3M |
| Operating Income | $-79.0M | $-65.5M | $-96.8M |
| R&D | $52.9M | $45.6M | $57.1M |
| G&A | $82.8M | $93.3M | $121.2M |
| Stock-Based Comp | $10.6M | $9.3M | $13.1M |
| D&A | $924.0K | $802.0K | $329.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-29.0M | $-32.8M | $-27.3M |
| Interest Income | $938.0K | $2.6M | $8.9M |
| Pre-Tax Income | $-108.0M | $-98.3M | $-124.0M |
| Income Tax | $1.8M | $3.9M | $2.8M |
| Continuing Ops | $-109.8M | $-102.2M | $-126.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-109.8M | $-102.2M | $-126.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-109.8M | $-102.2M | $-126.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $128.9M | $169.2M | $276.1M |
| Cash & Equivalents | $55.4M | $95.0M | $172.0M |
| Marketable Securities | — | $56.2M | $110.7M |
| Accounts Receivable | $12.7M | $15.4M | $20.3M |
| Inventory | $4.3M | $5.7M | $9.2M |
| Prepaid Expenses | $11.1M | $10.3M | $8.8M |
| Other Current Assets | $45.4M | $-13.4M | $-44.9M |
| Long-Term Assets | $6.7M | $9.1M | $9.6M |
| PP&E (Net) | $1.3M | $689.0K | $655.0K |
| Operating Leases | $2.5M | $1.7M | $849.0K |
| Other LT Assets | $3.0M | $6.8M | $8.1M |
| Total Assets | $135.6M | $178.3M | $285.7M |
| Current Liabilities | $23.9M | $31.2M | $45.9M |
| Accounts Payable | $5.5M | $6.5M | $10.9M |
| Current Leases | — | — | $785.0K |
| Other Current Liab | $18.4M | $24.7M | $34.2M |
| Long-Term Liabilities | $201.1M | $212.3M | $248.6M |
| Long-Term Debt | $97.5M | $98.6M | $121.7M |
| LT Operating Leases | $1.6M | $844.0K | $58.0K |
| Other LT Liab | $101.9M | $112.9M | $126.8M |
| Total Liabilities | $225.0M | $243.5M | $294.5M |
| Shareholders' Equity | $-89.4M | $-65.2M | $-8.8M |
| Retained Earnings | $-577.1M | $-679.3M | $-806.2M |
| AOCI | $-107.0K | $12.0K | $56.0K |
| Total L&E | $135.6M | $178.3M | $285.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-109.8M | $-102.2M | $-126.9M |
| Non-Cash Adjustments | $16.2M | $17.6M | $13.7M |
| Working Capital Changes | $6.0M | $8.3M | $16.4M |
| Cash from Operations | $-87.6M | $-76.4M | $-96.8M |
| Capital Expenditures | $254.0K | $194.0K | $295.0K |
| Cash from Investing | $1.1M | $-953.0K | $-20.6M |
| Debt Issuances | $95.8M | $0 | $24.5M |
| Cash from Financing | $97.1M | $116.9M | $194.6M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $10.6M | $39.6M | $77.2M |
| Beginning Cash | $45.6M | $56.2M | $95.8M |
| Ending Cash | $56.2M | $95.8M | $173.1M |
Frequently Asked Questions
How does UroGen Pharma Ltd. make money?
Oncology drug development focusing on novel mechanisms of action, Rare disease therapeutics targeting orphan indications, and Revenue from collaboration agreements and milestone payments with commercial partners.
What are the main risks for URGN?
High risk of clinical trial failure given the early-stage nature of the pipeline and lack of commercial product sales, Significant reliance on external financing due to accumulated losses exceeding $800M, Potential dilution from equity issuances totaling over $150M in recent periods, and Regulatory uncertainty surrounding approval of novel mechanisms in oncology.
What is URGN's competitive advantage?
Specialized scientific platform for identifying novel targets in difficult-to-treat diseases, Strategic partnerships that provide upfront funding and reduce capital expenditure burden, and a lean operational structure allowing for high R&D efficiency relative to revenue scale.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.